

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical product, comprising a pharmaceutical aqueous preparation containing at least one member selected from the group consisting of tranilast and a salt thereof in a packaging container through which the contents are visible and which blocks light in the wavelength range from 365 nm to 430 nm.
2. (Original) A pharmaceutical product according to Claim 1, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from 365 nm to 430 nm.
3. (Original) A pharmaceutical product according to Claim 2, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from 350 nm to 430 nm.
4. (Original) A pharmaceutical product according to Claim 2, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from 350 nm to 450 nm.

5. (Previously Presented) A pharmaceutical product according to Claim 1, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from 365 nm to 430 nm, 20% or lower in the wavelength range from 350 nm to 430 nm, and 20% or lower in the wavelength range from 350 nm to 450 nm.

6. (Original) A pharmaceutical product according to Claim 1, wherein the packaging container has an average light transmittance of 30% or higher in the wavelength range from 455 nm to 780 nm.

7. (Currently Amended) A pharmaceutical product according to Claim 1, wherein the pharmaceutical preparation further comprises at least one member selected from the group consisting of berberine, berberine, tannate, berberine chloride, berberine sulfate, B2 vitamins, flavin adenine dinucleotide, flavin mononucleotide, riboflavin, riboflavin phosphate, riboflavin acetate, riboflavin butyrate, hesperidin, methyl hesperidin, oxyquinoline, oxyquinoline sulfate, oxyquinoline phosphate, B2 vitamins, cyanocobalamin, mecobalamin, cobamamide, hydroxocobalamin, derivatives thereof, and salts thereof.

8. (Cancel)

9. (Original) A pharmaceutical product according to Claim 8, wherein tranilast and a salt thereof is present in a total proportion of 0.01 to 20% by weight based on the total amount of the pharmaceutical preparation.

10. (Currently Amended) A pharmaceutical product according to Claim 1, wherein the pharmaceutical aqueous preparation is an eye drop, eye wash, injection, externally applied skin medicine, nasal drop, or contact lens-care formulation.

11. (Currently Amended) A method for inhibiting photodegradation of tranilast or a salt thereof, comprising placing a pharmaceutical aqueous preparation comprising at least one member selected from the group consisting of tranilast and a salt thereof in a packaging container through which the contents are visible and which blocks light in the wavelength range from 365 nm and 430 nm.

12. (Cancel)

13. (Cancel)